Summary of findings for the main comparison. PRO 140 compared to placebo for treatment of people with HIV infection.
| PRO 140 compared to placebo for treatment of people with HIV infection | ||||||
| Patient or population: patients being treated for HIV infection Intervention: PRO 140 Comparison: placebo | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| Placebo | PRO 140 | |||||
| Antiviral response: 0.5 mg/kg | Study population | OR 3.00 (0.11 to 83.36) | 19 (1 study) | ⊕⊝⊝⊝ very low1,2 | ||
| 0 per 1000 | 0 per 1000 (0 to 0) | |||||
| Moderate | ||||||
| 0 per 1000 | 0 per 1000 (0 to 0) | |||||
| Antiviral response: 2 mg/kg | Study population | OR 27.44 (1.25 to 601.57) | 19 (1 study) | ⊕⊝⊝⊝ very low1,2 | ||
| 0 per 1000 | 0 per 1000 (0 to 0) | |||||
| Moderate | ||||||
| 0 per 1000 | 0 per 1000 (0 to 0) | |||||
| Antiviral response: 5 mg/kg | Study population | OR 439.09 (25.73 to 7493.14) | 40 (2 studies) | ⊕⊝⊝⊝ very low1,2 | ||
| 0 per 1000 | 0 per 1000 (0 to 0) | |||||
| Moderate | ||||||
| 0 per 1000 | 0 per 1000 (0 to 0) | |||||
| Antiviral response: 10 mg/kg | Study population | OR 145.67 (5.3 to 4004.91) | 21 (1 study) | ⊕⊝⊝⊝ very low1,2 | ||
| 0 per 1000 | 0 per 1000 (0 to 0) | |||||
| Moderate | ||||||
| 0 per 1000 | 0 per 1000 (0 to 0) | |||||
| Antiviral response: 162 mg weekly | Study population | OR 24.82 (1.17 to 527.12) | 21 (1 study) | ⊕⊝⊝⊝ very low1,2 | ||
| 0 per 1000 | 0 per 1000 (0 to 0) | |||||
| Moderate | ||||||
| 0 per 1000 | 0 per 1000 (0 to 0) | |||||
| Antiviral response: 324 mg weekly | Study population | OR 147.00 (5.35 to 4037.48) | 21 (1 study) | ⊕⊝⊝⊝ very low1,2 | ||
| 0 per 1000 | 0 per 1000 (0 to 0) | |||||
| Moderate | ||||||
| 0 per 1000 | 0 per 1000 (0 to 0) | |||||
| Antiviral response: 324 mg biweekly | Study population | OR 57.00 (2.59 to 1253.22) | 22 (1 study) | ⊕⊝⊝⊝ very low1,2 | ||
| 0 per 1000 | 0 per 1000 (0 to 0) | |||||
| Moderate | ||||||
| 0 per 1000 | 0 per 1000 (0 to 0) | |||||
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; OR: Odds ratio; | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
1 Randomization: method not specified; Allocation concealment: unclear; Blinding: method not specified. 2 Total number of events is less than 300.